Tetrameric cytokines with improved biological activity
The present invention concerns methods and compositions for forming cytokine-antibody complexes using dock-and-lock technology. In preferred embodiments, the cytokine-MAb DNL complex comprises an IgG antibody attached to two AD (anchor domain) moieties and four cytokines, each attached to a DDD (docking and dimerization domain) moiety. The DDD moieties form dimers that bind to the AD moieties, resulting in a 2:1 ratio of DDD to AD. The cytokine-MAb complex exhibits improved pharmacokinetics, with a significantly longer serum half-life than either naked cytokine or PEGylated cytokine. The cytokine-MAb complex also exhibits significantly improved in vitro and in vivo efficacy compared to cytokine alone, antibody alone, unconjugated cytokine plus antibody or cytokine-MAb DNL complexes incorporating an irrelevant antibody. In more preferred embodiment the cytokine is G-CSF, erythropoietin or INF-α2b.
Immunomedics, Inc.
B C C C C A A C B C A A C A A B C C C A C C C C C A
B82Y C07K C07K C07K C07K A61K A61P C07K B82Y C07K A61K A61K C07K A61P A61K B82Y C07K C07K C07K A61K C07K C07K C07K C07K C07K A61K
inventional inventional inventional additional additional inventional inventional additional inventional inventional inventional inventional additional inventional additional inventional additional inventional inventional inventional inventional additional inventional additional inventional inventional
Edmund A. David M. Chien-Hsing
Rossi Goldenberg Chang